Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 2002

View Archived Issues

4SC provides Recordati with compounds in drug research collaboration

Kosan and NCI to clinically develop geldanamycin analogues

New CRF antagonists identified at BMS

Millennium and Pfizer present new CCR5 antagonists for HIV infection

New inhibitors of VLA-4 receptors and cell adhesion presented by Aventis

Paratek patent covers novel antibacterial tetracyclines

New antimalarial agents prepared and tested by U. of Liverpool researchers

GSK scientists describe novel agents for herpesvirus infections

Novel 5-HT2C agonists with utility in obesity and other disorders

New series of retinoid RXR modulators claimed by Lilly and Ligand researchers

RegeneRx files IND for thymosin beta 4

Inspire discontinues development of INS-365 Respiratory for chronic bronchitis

Orally active MAPK inhibitor reduces VSMC proliferation and neointimal formation

Coley and GSK enter license agreement for cancer vaccines

Metalloporphyrin inhibits cardiomyocyte apoptosis by inducing heme oxygenase

Bay-43-9006 scheduled to enter phase III in 2003

FDA approves CMC amendment for ONYX-015

Postischemic IDN-6734 produces sustained improvement following myocardial ischemia/reperfusion

Improved gastrointestinal safety profile reported for licofelone in osteoarthritis

Cardioprotective effects of MX-1013 in rodent models of myocardial infarction

First safety and pharmacokinetic data of the thrombolytic BB-10153 in humans

Photodynamic therapy induces apoptosis within atherosclerotic plaques

D-63153, a new GnRH antagonist as a candidate for sex steroid-dependent diseases

FDA approves SuperGen's NDA to market Mitozytrex

Preclinical and early clinical data discussed for OSI-7836 in Frankfurt

Phase I/II trial initiated for LE-SN-38

Altana and Tanabe Seiyaku to develop and commercialize roflumilast in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...